Keros Therapeutics Inc (KROS)
60.35
-2.72
(-4.31%)
USD |
NASDAQ |
Nov 14, 16:00
60.35
0.00 (0.00%)
After-Hours: 17:35
Keros Therapeutics Debt to Equity Ratio: 0.00 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
September 30, 2024 | 0.00 |
June 30, 2024 | 0.00 |
March 31, 2024 | 0.00 |
December 31, 2023 | 0.00 |
September 30, 2023 | 0.00 |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.00 |
December 31, 2022 | 0.00 |
September 30, 2022 | 0.00 |
June 30, 2022 | 0.00 |
Date | Value |
---|---|
March 31, 2022 | 0.00 |
December 31, 2021 | 0.00 |
September 30, 2021 | 0.00 |
June 30, 2021 | 0.00 |
March 31, 2021 | 0.00 |
December 31, 2020 | 0.00 |
September 30, 2020 | 0.00 |
June 30, 2020 | 0.00 |
March 31, 2020 | 0.00 |
December 31, 2019 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2019
--
Maximum
Dec 2019
--
Average
--
Median
Dec 2019
Debt to Equity Ratio Benchmarks
Eli Lilly and Co | 2.185 |
Regeneron Pharmaceuticals Inc | 0.0677 |
Scholar Rock Holding Corp | -- |
NovaBay Pharmaceuticals Inc | -1.128 |
Palatin Technologies Inc | 0.00 |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 579.27M |
Total Liabilities (Quarterly) | 46.44M |
Shareholders Equity (Quarterly) | 532.84M |
Current Ratio | 19.03 |